This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Girard Gibbs Announces Class Action Lawsuit On Behalf Of Investors Of Immunomedics, Inc.

Girard Gibbs LLP announces that a class action lawsuit has been filed on behalf of purchasers of Immunomedics, Inc. (NASDAQ: IMMU) common stock between May 9, 2013 and October 9, 2013, inclusive, who are seeking to recover damages for alleged violations of the Securities Exchange Act of 1934.

Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. The Company has built a pipeline of therapeutic product candidates that are in clinical development.

In 2008, Immunomedics entered into a License and Collaboration Agreement with Nycomed GmbH, wherein Immunomedics issued Nycomed a worldwide license to develop, manufacture, and commercialize Veltuzumab, a humanized monoclonal antibody used for the treatment of all non-cancer indications. Immunomedics retained the rights to develop, manufacture, and commercialize Veltuzumab in the field of oncology. In September 2011, Takeda Pharmaceutical Company acquired Nycomed to form Takeda-Nycomed. As a result of the Agreement, Takeda-Nycomed was responsible for completing the clinical development and obtainment of all necessary regulatory approvals for Veltuzumab, as well as commercializing and manufacturing Veltuzumab for sale in non-cancer indications. During this time, however, Takeda-Nycomed and the Immunomedics were engaged in a dispute regarding a delay in the therapeutic compound’s development.

On October 9, 2013, Immunomedics issued a press release announcing that the Agreement with Takeda-Nycomed had been terminated. On this news, Immunomedics common stock dropped 5.9% on heavy trading volume. Moreover, on the previous day, October 8, 2013, Immunomedics common stock dropped nearly 12%, on very heavy trading volume, as news about the termination of the Agreement leaked into the market.

If you are a member of the Class described above and you meet certain legal requirements, you may file a motion with the Court to serve as lead plaintiff, no later than April 28, 2014. No action is required to remain a member of the Class. You may retain counsel of your choice or take no action and remain an absent member of the Class.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs